Incyte Corporation (LON:0J9P)
58.94
+0.38 (0.65%)
At close: Apr 25, 2025
Incyte Revenue
In the year 2024, Incyte had annual revenue of $4.24B USD with 14.76% growth. Incyte had revenue of $1.18B in the quarter ending December 31, 2024, with 16.32% growth.
Revenue
$4.24B
Revenue Growth
+14.76%
P/S Ratio
2.54
Revenue / Employee
$1.62M
Employees
2,617
Market Cap
8.60B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Incyte News
- 15 days ago - Incyte (INCY) Revenue Surges, But Stock Drops 20% - GuruFocus
- 18 days ago - Incyte to Report First Quarter Financial Results - Business Wire
- 20 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - These 20 worst-performing stocks in the S&P 500 sank 17% or more in March - Market Watch
- 4 weeks ago - Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico - GlobeNewsWire
- 5 weeks ago - Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib - Seeking Alpha
- 5 weeks ago - This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
- 5 weeks ago - Incyte downgraded to Neutral at Guggenheim on trial results for skin disease treatment - Seeking Alpha